

Effect of Oral Treprostinil on Hemodynamics in Pulmonary Arterial Hypertension (PAH)

FREEDOM-EV: Phase III, international, placebo-controlled, double-blind, event-driven study



690

participants with PAH who were taking a single oral PAH therapy


Sub Study

61

Participants volunteered for a hemodynamics sub-study:


Oral treprostinil
34

Placebo
27



PA compliance

26.4%




-6.0%


p=0.007



PVR




p=0.02



CO

11.3%



p=0.005

■ Oral treprostinil ■ Placebo

Change in geometric mean (%) from Baseline to Week 24; CO, cardiac output; PA, pulmonary artery; PVR, pulmonary vascular resistance

FREEDOM-EV



Increased pulmonary artery compliance may contribute to the increased exercise capacity and delayed clinical worsening of PAH seen in FREEDOM-EV

Khan, A et al. *Respir Med.* 2022;193:e106744. DOI:<https://doi.org/10.1016/j.rmed.2022.106744>